Eloralintide

Human clinical Weight Loss & Metabolism 3 sources

Eloralintide (LY3841136) is a novel, long-acting, selective amylin receptor agonist developed by Eli Lilly for the treatment of obesity. Research shows it mimics the natural hormone amylin to reduce appetite, decrease food intake, and promote significant weight loss, primarily through fat mass reduction.

01Dosing reference

Amount

1 mg to 9 mg

Frequency

Once weekly

Cycle

Continuous use in clinical trials (e.g., 48 weeks)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Amylin Receptor Activation

Eloralintide selectively binds to and activates the amylin receptors (AMY1R), mimicking the action of the native hormone amylin, which is co-secreted with insulin.

Satiety Modulation

Activation of these receptors in the brain increases feelings of fullness (satiety) and delays gastric emptying, leading to a reduction in caloric intake.

Weight and Fat Reduction

The sustained decrease in food intake results in significant body weight loss, with studies indicating that the weight lost is predominantly fat mass.

03Human evidence

In a Phase 2 trial, eloralintide produced clinically meaningful, dose-dependent reductions in body weight over 48 weeks, with up to 20% weight loss at the 9 mg dose.

Phase 2 clinical trial involving adults with obesity or overweight, comparing various doses (1 mg to 9 mg) of eloralintide to placebo.

Eloralintide lowered resting heart rate, an effect consistent with other non-selective amylin receptor agonists.

Observed in clinical studies evaluating the safety and tolerability of the compound.

04Preclinical evidence

Eloralintide selectively activates human AMY1R compared to human AMY3R and CTR, inducing weight loss mainly through fat mass reduction.

Rodent models used to evaluate receptor selectivity and body composition changes.

The compound induced decreased appetite, reduced food intake, and prolonged plasma calcium reduction.

Preclinical animal studies assessing the physiological effects of amylin receptor agonism.

05What is known vs. unknown

Reasonably established

Eloralintide is a selective amylin receptor agonist designed for once-weekly subcutaneous injection.
It has demonstrated up to 20% body weight reduction in Phase 2 clinical trials over 48 weeks.
The weight loss achieved is primarily due to a reduction in fat mass rather than lean muscle.
It works by modulating satiety and delaying gastric emptying, similar to the native hormone amylin.

Unknowns & limits

Long-term safety and efficacy beyond 48 weeks are still being evaluated in ongoing Phase 3 trials.
The exact cardiovascular outcomes and potential long-term effects on resting heart rate require further investigation.
Optimal combination strategies with other weight-loss medications (like GLP-1 agonists) are still under study.

06Safety & regulatory context

Regulatory statusEloralintide is currently an investigational drug and is not FDA-approved for any indication. In clinical trials, it has been generally well-tolerated, with a safety profile consistent with other amylin-based therapies. Common side effects may include gastrointestinal issues such as nausea, vomiting, and decreased appetite. It has also been noted to lower resting heart rate. As an investigational compound, it should only be used in the context of approved clinical trials.

07Compared with Cagrilintide

Eloralintide vs. Cagrilintide

Key difference

Eloralintide is a highly selective amylin receptor agonist, whereas cagrilintide is a non-selective amylin and calcitonin receptor agonist.

When researchers discuss each

Researchers discuss eloralintide when focusing on selective amylin receptor targeting for obesity, while cagrilintide is often discussed in the context of combination therapies (like CagriSema) for broader metabolic effects.

08Glossary

Amylin

A peptide hormone co-secreted with insulin from the pancreas that plays a role in glycemic regulation by slowing gastric emptying and promoting satiety.

Agonist

A substance that initiates a physiological response when combined with a receptor.

Satiety

The feeling of fullness and loss of appetite that occurs after eating.

09Knowledge check

Q1What is the primary mechanism of action for eloralintide?

Q2In Phase 2 clinical trials, what was the maximum average weight loss observed with eloralintide over 48 weeks?

Q3Which of the following best describes a documented limitation of the current clinical evidence for eloralintide?

Q4Which statement best captures the stated distinction between eloralintide and cagrilintide in the dossier?

Q5According to the dossier, which of the following correctly reflects eloralintide's regulatory status and commonly reported safety findings from trials?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.